Dosimetric and Economic Comparison of Interstitial High-Dose-Rate Brachytherapy to Stereotactic Body Radiation Therapy for Liver Lesions

Brachytherapy ◽  
2015 ◽  
Vol 14 ◽  
pp. S101 ◽  
Author(s):  
Brian A. Hrycushko ◽  
Jeffrey Meyer ◽  
Patrick Sutphin ◽  
Anil Pillai ◽  
Sanjeeva Kalva ◽  
...  
2016 ◽  
Vol 15 (6) ◽  
pp. 759-765 ◽  
Author(s):  
Antonio Pontoriero ◽  
Giuseppe Iatì ◽  
Dario Aiello ◽  
Stefano Pergolizzi

Aim: To evaluate the role of stereotactic body radiation therapy in the retreatment of locally recurrent cervical cancers. Brachytherapy is the main choice to treat gynecologic cancers. Methods: Patients with recurrent cervical cancer, previously submitted to radiotherapy, were treated with stereotactic body radiation therapy using a CyberKnife system (Accuray Incorporated, Sunnyvale, California) with a fiducial tracking system. Results: From August 2011 to October 2014, 5 patients have been treated. Median age was 81 years (range, 70-84 years). Two patients were diagnosed with adenocarcinoma endometrioid and 3 with squamous cell carcinoma. Toxicity was scored according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria. After a median follow-up of 12 months (range, 8-34 months), no severe (>grade 3) acute/late genitourinary or low gastrointestinal toxicity was observed. Conclusion: Our preliminary results of stereotactic body radiation therapy “simulating” high dose rate for recurrent cervical cancers confirm a minimal toxicity and an optimal outcome. The stereotactic body radiation therapy is an alternative to high dose rate brachytherapy for gynecologic tumors.


Sign in / Sign up

Export Citation Format

Share Document